Pien Tze Huang: The first subject has been enrolled in the Phase IIa clinical trial of PZH2108.

The announcement of Pai Zi Huang stated that the first subject had been enrolled in the Phase IIa clinical trial of the innovative drug PZH2108 tablet developed by the company. The drug is intended for the treatment of cancer pain, with a cumulative research and development investment of approximately 61 million yuan. As of the date of the announcement, according to the official website of the National Medical Products Administration, no other company has obtained the production batch approval for this product, and no other drug with the same target and indication as PZH2108 tablet has been approved for market.